Ligand Pharmaceuticals (LGND) Long-Term Investments (2010 - 2026)

Ligand Pharmaceuticals has disclosed Long-Term Investments across 17 years of filings, most recently posting $13.5 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $13.5 million, up 24.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.5 million (up 24.01% YoY), and the FY2025 annual result was $121.5 million, changed N/A from the prior year.
• Long-Term Investments came in at $13.5 million for Q1 2026 at Ligand Pharmaceuticals, down from $121.5 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $375.0 million in Q1 2022 to a low of $3.0 million in Q4 2022.
• The 5-year median for Long-Term Investments is $35.5 million (2024), against an average of $137.9 million.
• Across the five-year window, Long-Term Investments slumped 99.2% in 2022 and surged 319.83% in 2023, its largest moves.
• Ligand Pharmaceuticals' Long-Term Investments stood at $3.0 million in 2022, then soared by 319.83% to $12.6 million in 2023, then slipped by 13.39% to $10.9 million in 2024, then surged by 1013.41% to $121.5 million in 2025, then slumped by 88.86% to $13.5 million in 2026.
• The last three Long-Term Investments figures came in at $13.5 million (Q1 2026), $121.5 million (Q4 2025), and $42.0 million (Q3 2025), per Business Quant data.